TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dr Reddy’s Laboratories ( (RDY) ) has shared an update.
Dr. Reddy’s Laboratories announced the resignation of Mr. Jayanth Sridhar, the Global Head of Biologics, effective January 31, 2026. This change in senior management is part of the company’s ongoing adjustments to its leadership team, which could impact its strategic direction in the biologics sector.
The most recent analyst rating on (RDY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
Dr Reddy’s Laboratories’ overall stock score is driven by strong financial performance and a reasonable valuation. However, technical analysis indicates bearish trends, and the earnings call highlights both growth opportunities and challenges, particularly in the U.S. market. The absence of significant corporate events further focuses the score on these core components.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent player in the pharmaceutical industry, based in Hyderabad, India. The company specializes in the development and manufacturing of a wide range of pharmaceutical products, including generic drugs, active pharmaceutical ingredients, and biologics, with a focus on providing affordable and innovative medicines globally.
Average Trading Volume: 1,021,321
Technical Sentiment Signal: Hold
Current Market Cap: $11.29B
See more data about RDY stock on TipRanks’ Stock Analysis page.